132 related articles for article (PubMed ID: 9509971)
41. Engraftment of primates with G-CSF mobilized peripheral blood CD34+ progenitor cells expanded in G-CSF, SCF and MGDF decreases the duration and severity of neutropenia.
Andrews RG; Briddell RA; Hill R; Gough M; McNiece IK
Stem Cells; 1999; 17(4):210-8. PubMed ID: 10437984
[TBL] [Abstract][Full Text] [Related]
42. Delayed administration of filgrastim (G-CSF) following autologous peripheral blood stem cell transplantation (APBSCT) in pediatric patients does not change time to neutrophil engraftment and reduces use of G-CSF.
Pai V; Fernandez SA; Laudick M; Rosselet R; Termuhlen A
Pediatr Blood Cancer; 2010 May; 54(5):728-33. PubMed ID: 20063422
[TBL] [Abstract][Full Text] [Related]
43. Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization.
Sinitsyn Y; Malone A; Mandeli J; Grosskreutz C; Osman K; Scigliano E; Shi P; Isola L
Cytotherapy; 2009; 11(4):457-63. PubMed ID: 19499401
[TBL] [Abstract][Full Text] [Related]
44. Delayed administration of G-CSF until day +7 after autologous peripheral blood stem cell transplant is as effective in accelerating hematopoietic as day 0.
Sobrevilla-Calvo P; Zinser Sierra JW; Lara Medina FU; Acosta Barreda A; Calderón Flores E
Rev Invest Clin; 2002; 54(1):51-6. PubMed ID: 11995407
[TBL] [Abstract][Full Text] [Related]
45. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
McQuaker I; Haynes A; Stainer C; Byrne J; Russell N
Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673
[TBL] [Abstract][Full Text] [Related]
46. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK; Kaufman J
Transfusion; 2007 Apr; 47(4):629-35. PubMed ID: 17381621
[TBL] [Abstract][Full Text] [Related]
47. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
[TBL] [Abstract][Full Text] [Related]
48. Engraftment of patients with lymphoid malignancies transplanted with autologous bone marrow, peripheral blood stem cells or both.
Langenmayer I; Weaver C; Buckner CD; Lilleby K; Appelbaum FR; Longin K; Rowley S; Storb R; Singer J; Bensinger WI
Bone Marrow Transplant; 1995 Feb; 15(2):241-6. PubMed ID: 7773213
[TBL] [Abstract][Full Text] [Related]
49. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor.
Ford CD; Greenwood J; Anderson J; Snow G; Petersen FB
Transfusion; 2006 Feb; 46(2):193-8. PubMed ID: 16441594
[TBL] [Abstract][Full Text] [Related]
50. Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial.
Faber E; Pytlík R; Slabý J; Zapletalová J; Kozák T; Raida L; Papajík T; Zikesová E; Maresová I; Hamouzová M; Indrák K; Trnený M
Eur J Haematol; 2006 Dec; 77(6):493-500. PubMed ID: 17042769
[TBL] [Abstract][Full Text] [Related]
51. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
Bernstein SH; Fay JP; Christiansen NP; Pinero L; Shah D; Stephan M; Herzig GP
Clin Cancer Res; 1997 Sep; 3(9):1519-26. PubMed ID: 9815838
[TBL] [Abstract][Full Text] [Related]
52. Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF.
Jansen J; Thompson EM; Hanks S; Greenspan AR; Thompson JM; Dugan MJ; Akard LP
Bone Marrow Transplant; 1999 Jun; 23(12):1251-6. PubMed ID: 10414911
[TBL] [Abstract][Full Text] [Related]
53. Administration of granulocyte colony-stimulating factor from day 7 after autologous bone marrow transplantation: effects on neutropenia and duration of hospitalization.
Moreau P; Le Tortorec S; Mahé B; Legros L; Milpied N; Harousseau JL
Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):455-8. PubMed ID: 7538659
[TBL] [Abstract][Full Text] [Related]
54. G-CSF during large field radiotherapy reduces bone marrow recovery capacity.
Pape H; Orth K; Heese A; Heyll A; Kobbe G; Schmitt G; Niederbichler AD; Peiper M; Schwarz A; Boelke E
Eur J Med Res; 2006 Aug; 11(8):322-8. PubMed ID: 17052967
[TBL] [Abstract][Full Text] [Related]
55. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period.
Hornedo J; Solá C; Solano C; López JJ; Alonso S; Lluch A; Ojeda B; Garcia-Conde J; Cortés-Funes H;
Bone Marrow Transplant; 2002 May; 29(9):737-43. PubMed ID: 12040470
[TBL] [Abstract][Full Text] [Related]
56. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
[TBL] [Abstract][Full Text] [Related]
57. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
[TBL] [Abstract][Full Text] [Related]
58. Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy.
Waller CF; von Lintig F; Daskalakis A; Musahl V; Lange W
Bone Marrow Transplant; 1999 Jul; 24(1):19-24. PubMed ID: 10435729
[TBL] [Abstract][Full Text] [Related]
59. Granulocyte-macrophage colony-stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphoma.
Colombat P; Delain M; Desbois I; Domenech J; Binet C; Tabah I; Lamagnere JP; Linassier C
Bone Marrow Transplant; 1996 Aug; 18(2):293-9. PubMed ID: 8864437
[TBL] [Abstract][Full Text] [Related]
60. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
